Cytarabine/daunorubicin - Jazz Pharmaceuticals

Drug Profile

Cytarabine/daunorubicin - Jazz Pharmaceuticals

Alternative Names: CPX-351; Cytarabine/daunorubicin liposomal; Cytarabine:daunorubicin - Jazz Pharmaceuticals; Cytarabine:daunorubicin liposome injection - Jazz Pharmaceuticals; Daunorubicin/cytarabine; Liposomal AraC-Daunorubicin CPX-351; NS 87; VYXEOS

Latest Information Update: 13 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celator Pharmaceuticals
  • Developer Cardiff University; Celator Pharmaceuticals; Cincinnati Childrens Hospital Medical Center; Fred Hutchinson Cancer Research Center; Jazz Pharmaceuticals plc; National Cancer Institute (USA); Stanford University; The Leukemia & Lymphoma Society; University of Texas M. D. Anderson Cancer Center
  • Class Anthracyclines; Antineoplastics; Arabinonucleosides; Cytostatic antibiotics; Daunorubicins; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA intercalators; DNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute myeloid leukaemia
  • Phase III Myelodysplastic syndromes
  • Phase II Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Lymphoma

Most Recent Events

  • 06 Aug 2018 Jazz Pharmaceuticals enters into a collaboration with University of Texas M. D. Anderson Cancer Center for multiple haematological malignancies
  • 03 Aug 2018 Jazz Pharmaceuticals receives new technology add-on payment from the U.S. Centres for Medicare and Medicaid Services for daunorubicin/cytarabine for Acute myeloid leukemia
  • 19 Jul 2018 Updated adverse events data from a phase III trial in Acute myeloid leukaemia released by Jazz Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top